The ‘Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT)’ project is a collaborative effort supported by the National Institutes of Health (NIH) and United States Food & Drug Administration (FDA) to explore how adaptive clinical trial design might improve the evaluation of drugs and medical devices. ADAPT-IT uses the National Institute of Neurologic Disorders & Stroke-supported Neurological Emergencies Treatment Trials (NETT) network as a ‘laboratory’ in which to study the development of adaptive clinical trial designs in the confirmatory setting. The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial was selected for funding by the NIH-NINDS at the start of ADAPT-IT and is currently an ongoing phase III trial of tight glucose control in hyperglycemic acute ischemic stroke patients. Within ADAPT-IT, a Bayesian adaptive Goldilocks trial design alternative was developed. The SHINE design includes response adaptive randomization, a sample size re-estimation, and monitoring for early efficacy and futility according to a group sequential design. The Goldilocks design includes more frequent monitoring for predicted success or futility and a longitudinal model of the primary endpoint. Both trial designs were simulated and compared in terms of their mean sample size and power across a range of treatment effects and success rates for the control group. As simulated, the SHINE design tends to have slightly higher power and the Goldilocks design has a lower mean sample size. Both designs were tuned to have approximately 80% power to detect a difference of 25% versus 32% between control and treatment, respectively. In this scenario, mean sample sizes are 1,114 and 979 for the SHINE and Goldilocks designs, respectively. Two designs were brought forward, and both were evaluated, revised, and improved based on the input of all parties involved in the ADAPT-IT process. However, the SHINE investigators were tasked with choosing only a single design to implement and ultimately elected not to implement the Goldilocks design. The Goldilocks design will be retrospectively executed upon completion of SHINE to later compare the designs based on their use of patient resources, time, and conclusions in a real world setting. ClinicalTrials.gov NCT01369069 June 2011.
The rapidly accelerating translation of biomedical advances is leading to revolutionary therapies that are often inaccessible to historically marginalized populations. We identified and synthesized recent guidelines and statements to propose 7 strategies to integrate equity within translational research in neurology: (1) learn history; (2) learn about upstream forces; (3) diversify and liberate; (4) change narratives and adopt best communication practices; (5) study social drivers of health and lived experiences; (6) leverage health technologies; and (7) build, sustain, and lead culturally humble teams. We propose that equity should be a major goal of translational research, equally important as safety and efficacy. ANN NEUROL 2024;95:432–441
26 August 2021 in Journal of Stroke and Cerebrovascular Diseases
Background: Traditionally in acute stroke clinical trials, the primary clinical outcomeemployed is a dichotomized modified Rankin Scale (mRS). New statisticalmethods, such as responder analysis, are being used in stroke studies toaddress the concern that baseline prognostic variables, such as strokeseverity, impact the likelihood of a successful outcome. Responder analysisallows the definition of success to vary according to baseline prognosticvariables, producing a more clinically relevant insight into the actualeffect of investigational treatments. It is unclear whether or notstatistical analyses should adjust for prognostic variables when responderanalysis is used, as the outcome already takes these prognostic variablesinto account. This research aims to investigate the effect of covariateadjustment in the responder analysis framework in order to determine theappropriate analytic method. Methods: Using a current stroke clinical trial and its pilot studies to guidesimulation parameters, 1,000 clinical trials were simulated at varyingsample sizes under several treatment effects to assess power and type Ierror. Covariate-adjusted and unadjusted logistic regressions were used toestimate the treatment effect under each scenario. In the case ofcovariate-adjusted logistic regression, the trichotomized National Instituteof Health Stroke Scale (NIHSS) was used in adjustment. Results: Under various treatment effect settings, the operating characteristics of theunadjusted and adjusted analyses do not substantially differ. Power and typeI error are preserved for both the unadjusted and adjusted analyses. Conclusions: Our results suggest that, under the given treatment effect scenarios, thedecision whether or not to adjust for baseline severity when using aresponder analysis outcome should be guided by the needs of the study, astype I error rates and power do not appear to vary largely between themethods. These findings are applicable to stroke trials which use the mRSfor the primary outcome, but also provide a broader insight into theanalysis of binary outcomes that are defined based on baseline prognosticvariables. Trial registration: This research is part of the Stroke Hyperglycemia Insulin Network Effort(SHINE) trial, Identification Number NCT01369069.
Historically underrepresented groups in biomedical research have continued to experience low representation despite shifting demographics. Diversity fosters inclusive, higher quality, and innovative team science. One avenue for diversifying research teams is integrating diversity-focused initiatives into Clinical and Translational Science Award (CTSA) Programs, such as the integrated Translational Health Research Institute of Virginia (iTHRIV). In 2020, iTHRIV participated in Building Up, developed by the University of Pittsburgh CTSA, and intended to increase representation and improve career support for underrepresented groups in the biomedical workforce. Drawing lessons from this study, iTHRIV implemented the "inspiring Diverse Researchers in Virginia" (iDRIV) program. This yearlong program provided education, coaching, mentoring, and sponsorship for underrepresented early career investigators in the biomedical workforce. To date, 24 participants have participated in the program across three cohorts. Participants have been predominantly female (92%), with 33% identifying as Hispanic/Latinx, 29% as Black, and 13% as Asian. Notably, 38% of scholars have subsequently achieved at least one accomplishment, such as receiving a local research honor or award and an extramural funding award from a foundation or federal agency. The iTHRIV iDRIV program serves as a model for providing career support to developing investigators from underrepresented backgrounds, with the overall goal of improving patient health.